AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06666504 — intervention group
Intervention type: OTHER
Intervention: Combined Retrospective and Prospective Data Analysis
Description: Collection of both retrospective and prospective data all ready available for participant
Study NCT06667700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Description: Molnupiravir administered orally as two 400 mg film-coated tablets every 12 hours for 5 days (a total of 10 consecutive doses)
Study NCT06667700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Molnupiravir-matching placebo administered orally as two film-coated tablets every 12 hours for 5 days (a total of 10 consecutive doses)
Study NCT06481995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrogammin
Description: Fibrogammin is administered according to the Summary of product characteristics (SmPC) after measured blood loss exceeds 700 ml and bleeding is ongoing
Study NCT05512039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox 50 Unit Injection
Description: Participants will be randomized to either receive a standard dose (100 units) or reduced dose (50 units) of onabotulinumtoxinA. If a participant has decreased symptom relief they may receive repeat treatment up to twice during the 12 month follow-up period, with minimum 4 month intervals between treatments.
Study NCT05210946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Advanced non-small cell lung cancer patients with known FGFR 1-3 alterations (including but not limited to FGFR amplification, rearrangement/fusion, mutation, etc.) who have failed standard therapy will be enrolled in this study once they have signed the informed consent form (ICF) and been identified as eligible in screening. The patients will receive 13.5 mg of pemigatinib once a day (QD) orally following a 2-week administration/~1-week interruption regimen. They will be dosed until disease progression or intolerable toxicity. During treatment, clinical tumor imaging evaluation will be performed according to RECIST v1.1 every 6 weeks (± 7 days) and then every 9 weeks (± 7 days) after week 48. Safety will be assessed according to NCI-CTCAE 5.0.
Study NCT05409638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy to manage cancer-related fatigue
Description: Participation will consist of attending 90-minute virtual groups for 4 consecutive weeks on cancer-related fatigue. During the 4 weeks, participants will be asked to participate in activities, participate in group discussions, and complete homework.
Study NCT05783050 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wei Nasal Jet Tube
Description: The purpose of this procedure is to provide safe oxygenation and ventilation. While providing oxygen support, nasal cannula, classical oxygen mask can be used, as well as new generation oxygenation devices.
Study NCT05783050 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Cannula Oxygen Support
Description: The purpose of this procedure is to provide safe oxygenation and ventilation. While providing oxygen support, nasal cannula, classical oxygen mask can be used, as well as new generation oxygenation devices.
Study NCT06118697 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophageal stimulation with high resolution esophageal manometry and nutritive oral feeding therapy
Description: Subjects will be given weekly pharyngo-esophageal stimulation guided by high resolution impedance manometry for 4 weeks. During this time of study intervention, every feed will start with nutritive oral stimulation with at least 5 mL of the infant's prescribed diet.
Study NCT05479058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Administered orally once daily
Study NCT05479058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally once daily
Study NCT05512039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox 100 Unit Injection
Description: Participants will be randomized to either receive a standard dose (100 units) or reduced dose (50 units) of onabotulinumtoxinA. If a participant has decreased symptom relief they may receive repeat injection up to twice during the 12 month follow-up period, with minimum 4 month intervals between treatments.
Study NCT06148181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-141
Description: Infusion; intravenous (IV)
Study NCT06148181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABBV-141
Description: Infusion; IV
Study NCT06148181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-141
Description: Injection; subcutaneous (SC)
Study NCT06148181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABBV-141
Description: Injection; SC
Study NCT06310005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3006337
Description: BI 3006337
Study NCT06310005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT06438315 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04728542 — intervention group
Intervention type: DEVICE
Intervention: ORIGIN PS System
Description: 70 surgeries with the ORIGIN PS System
Study NCT04728542 — intervention group
Intervention type: DEVICE
Intervention: VANGUARD PS System
Description: 70 surgeries with the VANGUARD System
Study NCT04842123 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Electrocardiogram
Description: Simultaneous assessment of the heart rhythm determined from a 12-lead ECG and the Garmin ECG software algorithm heart rhythm classification on single-lead ECG data derived from the wearable device. All participants will record three simultaneous 12-lead and single-lead ECGs.
Study NCT05586880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: EnXtra 300 mg/ capsule
Description: One capsule to be taken 3±0.5 hours prior to second gaming session on Day 1 followed by 1 capsule daily after breakfast for 5 days
Study NCT05586880 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline cellulose (MCC) 300mg
Description: One capsule to be taken 3±0.5 hours prior to second gaming session on Day 1 followed by 1 capsule daily after breakfast for 5 days
Study NCT04194476 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: StatStrip blood glucose meter and strips
Description: We'll use a drop of heel-stick blood to test blood glucose on the glucose meter. About 200-300 ul of blood from the same stick site will be collected, centrifuged to get plasma for testing of glucose level in a laboratory biochemistry analyzer.
Study NCT06234423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUSP06
Description: Antibody drug conjugate (ADC)
Study NCT05582915 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: 4 ml of blood will be collected into EDTA tube for proteomic analysis at visit 0 and visit 1
Study NCT06556043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cM1 transcranial direct current stimulation
Description: During the 5-day skill acquisition phase, all participants will undertake a 20-minute session of learning a sequential ankle tracking task with their non-dominant (for healthy adults) or affected (for patients with stroke) foot each day, using a custom-built ankle tracking system. The cM1 group will receive AtDCS stimulation at 2 mA during acquisition phase.
Study NCT06556043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cPPC transcranial direct current stimulation
Description: During the 5-day skill acquisition phase, all participants will undertake a 20-minute session of learning a sequential ankle tracking task with their non-dominant (for healthy adults) or affected (for patients with stroke) foot each day, using a custom-built ankle tracking system. The cPPC group will receive AtDCS stimulation at 2 mA during acquisition phase.
Study NCT06556043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iCBM transcranial direct current stimulation
Description: During the 5-day skill acquisition phase, all participants will undertake a 20-minute session of learning a sequential ankle tracking task with their non-dominant (for healthy adults) or affected (for patients with stroke) foot each day, using a custom-built ankle tracking system. The iCBM group will receive AtDCS stimulation at 2 mA during acquisition phase.
Study NCT06556043 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham transcranial direct current stimulation
Description: For the Sham group, the montages of the paired electrode placements will be randomly selected from the other three pairs using blocks of size 3, so that the three types of montages will have equal opportunities to be used in the Sham group. The intensity will be set at 0 mA for the Sham group. There will be a 30-second ramp-up for the Sham group. Once the current reaches 2 mA in the ramp-up period, it will drop to 0 mA for the entire 20 minutes during learning for the Sham group.
Study NCT04972578 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suture Button vs Screw Fixation
Description: Syndesmotic fixation utilizing suture button fixation versus Screw Fixation (placing one or two screws across the syndesmosis)
Study NCT05216562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exosome-MSC Intravenous injection
Description: Intravenous injection of Exosome-MSC
Study NCT05216562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Intravenous Injection
Description: Intravenous injection of Placebo
Study NCT05216562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: COVID-19 Standard Treatment
Description: Specific drugs considered standard treatment for COVID-10 by each location may vary
Study NCT05216562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COVID-19 Standard Treatment
Description: Specific drugs considered standard treatment for COVID-10 by each location may vary
Study NCT05640115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ureteral Stent
Description: A ureteral stent is a soft, hollow tube that is placed temporarily into the ureter. The stent allows the urine to drain. The stent has a coil on each end that keeps it from moving. The top end coils in the kidney and the lower end coils inside the bladder.
Study NCT05640115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Nephrostomy Tube Placement
Description: A percutaneous nephrostomy is the placement of a small, flexible rubber tube (catheter) through your skin into your kidney to drain your urine. It is inserted through your back or flank.
Study NCT05597982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kidney Transplant Fast Track (KTFT)
Description: Streamlined KT evaluation involving completion of most or all testing on the same day a patient arrives for their first pre-transplant clinic appointment. Or, a transplant clinic scheduler secures testing within a 4 week period.
Study NCT05597982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer Navigation (PN)
Description: Uses trained, previous KT recipients who meet weekly to monthly with patient participants to provide tailored information and assistance in completing the necessary steps to proceed to transplant.
Study NCT05651711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocatinlimab
Description: Rocatinlimab will be administered through a subcutaneous (SC) injection.
Study NCT05651711 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The matching placebo will be administered through a SC injection.
Study NCT06598306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarlatamab
Description: Administered by SC injection.
Study NCT04656431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized pyruvate (13C)
Description: Given intravenously (IV) injection prior to imaging
Study NCT04656431 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Description: MRI scan takes an image of brain and/or spinal cord and will take up to 45 minutes to complete
Study NCT06235723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Virtual Reality was used before and during punctures. For every observation patients underwent either port puncture or peripheral venous puncture. One examination was carried out according to the Standard-of-Care. The other one was carried out with the additional use of VR. Participants watched a passive distraction video.
Study NCT05226702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAC-2
Description: Intramuscular vaccine against SARS-CoV-2
Study NCT05226702 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Intramuscular injection of saline placebo
Study NCT06522529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy
Description: The multifaceted implementation strategy consist in a process of improvement by reference to a prior baseline clinical audit. It implies a local context analysis, identifying barriers to improvements in clinical practice, and developing and implementing a plan of action for improving adherence to pre-established criteria. The goal is to establish interprofessional processes within the teams, in order to: examine the barriers that hinder the use of evidence in fostering best practices; and contribute to the development of implementation programmes for overcoming such obstacles.
Study NCT05548777 — intervention group
Intervention type: DRUG
Intervention: Andexanet alfa
Description: Andexanet alfa
Study NCT05548777 — intervention group
Intervention type: DRUG
Intervention: 4F-PCC
Description: Four-Factor Prothrombin Complex Concentrate (4F-PCC)
Study NCT04980794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-child intervention
Description: Families (two adult caregivers, child between 4 and 17) receive four interactive, asynchronous psychoeducation modules to review on their own paired with weekly contact with a communication coach and two live sessions with a communication coach to discuss psychoeducation, receive feedback on their interactions, and practice a communication technique.
Study NCT04980794 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-study Intervention
Description: Families (two adult caregivers) receive information in a newsletter format to review on their own, paired with weekly contact from a communication coach to answer questions and direct their attention toward specific topics in the newsletter.
Study NCT05757700 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 19(T2)28z1xx TRAC T cell
Description: Participants will be treated with escalating doses of modified T cells.~Dose level -1: 3 x 10\^6 Dose level 1: 10 x 10\^6 Dose level 2: 30 x 10\^6 Dose level 3: 100 x 10\^6
Study NCT05990738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764532
Description: BI 764532
Study NCT05990738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan
Study NCT06280963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: muscle energy technique
Description: in muscle energy technique, the target is gluteus maximus muscle ( hip extension ) and repeat the method from three to five times .
Study NCT06280963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: posterior innominate mobilization
Description: in posterior innominate mobilization ( grade 3 mobilization ) , frequency of mobilizations is 30 oscillations , 3 sets per session ( every set has 30 oscillations )
Study NCT06280963 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: conventional treatment
Description: conventional treatment include~* TENS ( 45 minutes of conventional TENS )~* Ultrasound (pulsed mode 1:1 ,5 min .1.5W/cm2 )~* Stretching exercises ( hamstrings ,hip flexors and hip adductors)~* Strengthening exercises (lower abdomen and glutes muscles )~* Lumpopelvic stabilization exercise
Study NCT05458622 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample
Description: - Total volume of blood (on each sampling occasion): 54,5mL.~* Whole blood will be collected in EDTA, 1 tube of 10 mL for DNA (genotyping, methylation arrays; at baseline for genotyping and at EOS visit for methylation arrays). From this, an aliquot of 0.5 mL for baseline cell numbers (cell proportions, CyTOF/flow cytometry) at all time points; capture of leukocytes for blood single cell RNA seq. at all time points and 5 mL for cell stimulations for cell metabolome (C13 to be added), and 1 tube of 10 mL for cell stimulations (CyTOF) at baseline.Tempus tube: 1 tube of 3 mL for RNA, 1 tube of 3mL for whole blood RNA seq.; to be taken at all time points. Plasma will be obtained and aliquoted from these tubes; to be obtained at all time points.~* Serum: 2 tubes of 10 mL without anticoagulant for measurements of anti-drug antibodies, hydroxychloroquine levels, cytokines and analytes, proteome, and autoantibodies; to be taken at all time points.
Study NCT05990738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single agent chemotherapy
Description: single agent chemotherapy
Study NCT05506956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flotetuzumab
Description: Patients enrolled on dose level 1 (DL1) will receive flotetuzumab by continuous infusion using multi-step lead-in dosing, and then 500 ng/kg/day on days 7-28. After one cycle, all patients will undergo a bone marrow biopsy to assess response including assessment of minimal residual disease (MRD). Patients who fail to achieve a CR, CRi, CRh (complete remission with partial hematologic recovery), or MLFS may continue with subsequent induction cycles as a continuous infusion up to a total of five cycles. If there is evidence of response (CR, CRi, CRh, or MLFS) and the toxicities of treatment are acceptable, patients will be eligible for two consolidation cycles. Additional bone marrow biopsies for response assessment will be performed after the second cycle. If there is a need to de-escalate dosing based on toxicity, then patients will be enrolled on DL-1 using multi-step lead-in dosing, and then 300 ng/kg/day on days 5-28 of the first cycle and days 1-28 of subsequent cycles.
Study NCT06561763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab,Toripalimab，Cisplatin, albumin paclitaxel, capecitabine
Description: Albumin paclitaxel 200g/m2, intravenous drip administration, d1; Cisplatin 60 mg/m2， Intravenous , d1; Capecitabine, 1000mg/m2, orally administered D1-14； Triprolizumab injection 240mg, intravenous D1; Nivolumab 400mg, intravenous D1; Q3W 1 cycle, 3 cycles Period, 3 weeks in total
Study NCT06561763 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimotuzumab,Toripalimab，Cisplatin, Gemcitabine
Description: Cisplatin 80 mg/m2， Intravenous drip administration, d1; Gemcitabine, 1000mg/m2,Intravenous ，D1,D8； Triprolizumab injection 240mg, intravenous ； Nivolumab 400mg, intravenous； Q3W 1 cycle, 3 cycles
Study NCT04496349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-115
Description: QOD, 2 weeks on, 1 week off, in repeated 21-day cycles
Study NCT04496349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-2575
Description: APG-2575 given orally each day in cycle, in repeated 21-day cycles
Study NCT06286046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat
Description: Tablets
Study NCT06446869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gyntima Menopause
Description: Combination of Levilactobacillus brevis KABP-052, Lactiplantibacillus plantarum KABP-051 and Pediococcus acidilactici KABP-021
Study NCT06446869 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT05108948 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality of life questionnaires
Description: Oswestry Disability Index Scoliosis Research Society-22R Short Form 36 Health Survey Questionnaire Tobacco, Alcohol, Prescription medication, and other Substance use Core Outcome Measures Index : back and neck
Study NCT05108948 — intervention group
Intervention type: PROCEDURE
Intervention: Radiography
Description: Spinal radiography : full, face, profile
Study NCT05458622 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Urine sample
Description: - Urine: 100 mL which will be centrifuged. The pellet will be frozen, and the urine supernatant will be aliquoted;
Study NCT06251180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocbrutinib
Description: orally once daily in a 21-day cycle for eight cycles, and as maintenance for 2 years.
Study NCT06251180 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 administered intravenously once on Day 1 in a 21-day cycle for eight cycles.
Study NCT06251180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
Study NCT06251180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 50 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.
Study NCT06251180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristin
Description: 1.4 mg/m2 administered intravenously once on Day 1 or 2 in a 21-day cycle for six cycles.